Novacyt S.A. (LON:NCYT – Get Free Report) traded up 3.1% during mid-day trading on Thursday . The company traded as high as GBX 50 ($0.64) and last traded at GBX 50 ($0.64). 79,305 shares were traded during trading, a decline of 32% from the average session volume of 116,097 shares. The stock had previously closed at GBX 48.50 ($0.62).
Novacyt Price Performance
The firm has a market cap of £35.32 million, a P/E ratio of -138.89 and a beta of -1.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 5.09 and a quick ratio of 4.46. The firm’s 50 day moving average is GBX 56.66 and its 200 day moving average is GBX 53.89.
Novacyt Company Profile
Novacyt SA, together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments.
See Also
- Five stocks we like better than Novacyt
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Sales Breakout Sends This Semiconductor Stock to Record High
- Stock Market Upgrades: What Are They?
- Surprise Buying Opportunity on This Dividend Aristocrat
- 3 Grocery Stocks That Are Proving They Are Still Essential
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for Novacyt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novacyt and related companies with MarketBeat.com's FREE daily email newsletter.
